Alethio Therapeutics has raised $90 million (£67 million) to take a new essential thrombocythemia (ET) antibody, ATX-011, into its first human studies. The Oxford, UK, company announced the oversubscribed Series A financing on November 5, 2026.
It is real momentum for ET research. It is not a new treatment option.
Alethio describes ATX-011 as still in preclinical development. Alethio’s CEO now expects trial enrollment to begin in the first half of 2028, subject to regulatory processes.
What Is ATX-011, and How Is It Supposed to Work?
ATX-011 is a monoclonal antibody that targets G6B, a protein found on platelets and on megakaryocytes, the bone marrow cells that produce platelets.
Alethio’s idea has two parts:
- Lower platelets directly. The antibody is designed to help the body clear platelets faster, rather than suppress the bone marrow.
- Reach the disease source. Alethio reports that G6B also appears on MPN-initiating stem cells, but not on healthy stem cells. It also appears on megakaryocytes linked to bone marrow fibrosis. The company hopes this could lead to disease modification.
That second part is a hypothesis. No one has shown it in a patient.
Alethio describes the approach as independent of driver mutation. That matters because CALR-targeted antibodies would not apply to the 70% to 80% of ET patients who have no CALR mutation, according to the company’s abstract. One limit: the patient samples described in the abstract carried JAK2 or CALR mutations. It reports no results in MPL-mutated or triple-negative ET.
What Do the Early Results Actually Show?
The data come from abstract 674, set for oral presentation at the American Society of Hematology (ASH) Annual Meeting in New Orleans on December 13, 2026. It is a conference abstract, not a full journal paper, and its authors include Alethio staff and the company’s scientific founders.
Patient samples
Researchers analyzed samples from more than 100 patients with JAK2- or CALR-mutated MPNs, along with matched healthy donors, to search for a target on mutant cells. That work pointed to G6B.
Laboratory tests
In the lab, ATX-011 did not directly activate or clump human platelets. It also did not affect megakaryocyte maturation. This matters because G6B helps regulate both platelets and megakaryocytes.
Monkey study
In two nonhuman primates:
- Platelets fell 80% at 96 hours.
- Platelets recovered as the antibody left the body, so any effect would likely depend on repeat dosing.
- Hemoglobin and white blood cell counts did not change.
- Inflammatory cytokines, CD40L, and D-dimer did not change, which the authors read as no sign of platelet activation or clotting problems.
The company’s modeling predicts dosing every three to four weeks could keep platelets normal in ET patients. That is a prediction. It has not been tested.
Two animals cannot establish a safe human dose, long-term tolerability, fewer blood clots, or disease modification. Sofinnova Partners’ Graziano Seghezzi, whose firm co-led the round, named the central risk himself in European Biotechnology: “The main uncertainty is the one you have with any first-in-class drug: whether the results we see in the lab will translate in patients.”
When Could Human Trials Begin?
The best current estimate is the first half of 2028. CEO Rohit Batta gave that timing to European Biotechnology and it also appears in BioPharma Dive. The ASH abstract lists a Phase 1/2a study as planned for 2027, so patients may see both dates.
The planned study has two parts. The second part includes platelet normalization at 12 weeks as an early proof-of-concept readout.
Where Is the $90 Million Going?
Alethio says the money will carry ATX-011 through Phase 1/2a studies in ET, up to Phase 3 readiness, and move other MPN programs closer to human testing.
- Investors: Sofinnova Partners and RA Capital co-led the round, alongside founding investor Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford.
- Founders: Oxford professors Adam Mead and Beth Psaila.
- Other programs: Trade reports describe a G6B antibody-drug conjugate for myelofibrosis and a mutant CALR program. Both are earlier-stage work.
What This Means for You
If you have ET, nothing about your care changes today. ATX-011 is experimental, it is not FDA-approved, and no trial is enrolling.
ET patients already have options. Hydroxyurea, anagrelide, and interferons are used today, and the FDA approved Besremi (ropeginterferon alfa-2b) for adults with ET in August 2026. The right choice depends on your age, clot history, symptoms, and tolerance, which is a conversation for your hematologist.
The news still matters. A $90 million bet tells you serious investors see ET as more than a platelet-count problem. Patients have good reason to agree. Fatigue, headaches, clots, treatment side effects, and fear of progression to myelofibrosis are the issues that shape daily life.
That is the standard ATX-011 will have to meet. Lower platelets are the first test. Fewer clots, fewer symptoms, and durable disease control are the ones that count.
Resources to Help You Take the Next Step
- MPN Clinical Trial Finder: See what is open now, since ATX-011 is not yet in trials
- MPN Specialist Locator: Locate a doctor who treats MPNs every day
- What Is Essential Thrombocythemia?: Review the basics
- Financial Patient Assistance Programs: Find help with treatment costs
Frequently Asked Questions About ATX-011
What is ATX-011?
ATX-011 is an experimental monoclonal antibody from Alethio Therapeutics. It targets G6B, a protein on platelets and megakaryocytes, and is being developed first for essential thrombocythemia.
When will ATX-011 clinical trials start?
Alethio’s CEO expects enrollment to begin in the first half of 2028, subject to regulatory processes. The company’s ASH abstract lists a Phase 1/2a study as planned for 2027.
How is ATX-011 different from current ET treatments?
Alethio designed ATX-011 to help the body clear platelets faster rather than suppress the bone marrow. The company also hopes it can reach disease-driving cells. Neither idea has been proven in patients.
Would ATX-011 work for both JAK2 and CALR mutations?
Alethio is developing it to work regardless of driver mutation, and G6B was identified in samples from JAK2- and CALR-mutated patients. Whether it works in any mutation group has not been tested in people.
References
- Alethio Therapeutics financing announcement, November 5, 2026
- ASH 2026 abstract 674: Development of ATX-011
- European Biotechnology, November 5, 2026
- BioPharma Dive, November 5, 2026
- The ASCO Post, FDA approval of ropeginterferon alfa-2b for ET, August 2026
Medical Disclaimer
This article is based on company announcements, trade reporting, and a conference abstract cited above. The content is for educational and patient advocacy purposes. It is not medical advice and is not a substitute for consultation with a qualified hematologist or MPN specialist. Treatment decisions should always be made in partnership with your healthcare team.
About the Author
David Wallace is a polycythemia vera patient advocate, writer, and the founder of PV Reporter and MPN Cancer Connection. Since launching PV Reporter in 2013, he has built one of the most comprehensive patient resource hubs for myeloproliferative neoplasms, including a doctor-vetted MPN specialist locator and a free clinical trial finder. David attends the American Society of Hematology annual meeting with press credentials and writes about emerging MPN research from the patient perspective.
Diagnosed with PV in May 2009 and now in complete molecular remission, his advocacy work has supported MPN patients and caregivers around the world.
